WO2007032591A1 - Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer - Google Patents

Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer Download PDF

Info

Publication number
WO2007032591A1
WO2007032591A1 PCT/KR2006/001990 KR2006001990W WO2007032591A1 WO 2007032591 A1 WO2007032591 A1 WO 2007032591A1 KR 2006001990 W KR2006001990 W KR 2006001990W WO 2007032591 A1 WO2007032591 A1 WO 2007032591A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cells
fpp
disease
angiogenesis
Prior art date
Application number
PCT/KR2006/001990
Other languages
English (en)
Inventor
Jung Ae Kim
Eung Seok Lee
Original Assignee
Industry-Academic Cooperation Foundation, Yeungnam University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020060046746A external-priority patent/KR100779610B1/ko
Application filed by Industry-Academic Cooperation Foundation, Yeungnam University filed Critical Industry-Academic Cooperation Foundation, Yeungnam University
Publication of WO2007032591A1 publication Critical patent/WO2007032591A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a composition
  • l-furan-2-yl- 3-pyridin-2-yl-pro ⁇ enone having an anti-angiogenic activity and a cancer growth inhibitory activity.
  • Angiogenesis is a process of creating capillary blood vessels from pre ⁇ existing microvascular networks. Angiogenesis normally occurs during embryonic development, tissue regeneration, wound healing and corpus luteum development that is a change in cyclical female reproductive system; in any case, neovascularization is strictly regulated to progress (Folkman J et al., Int. Rev. Exp. Pathol., 16, pp207-248, 1976).
  • Angiogenesis is a complex process that generally includes the degradation of vascular basement membrane by proteases released by the stimuli of proangiogenic factors! the migration and proliferation of endothelial cells; the formation of lumen due to differentiation of endothelial cells! the reconstruction of blood vessels! and the generation of new capillary vessels.
  • angiogenesis there are diseases induced by angiogenesis that is not regulated autonomously but grows morbidly.
  • diseases associated with angiogenesis occurring in pathological states are exemplified by hemangioma, angiofibroma, vascular malformation and cardiovascular diseases, such as arteriosclerosis, vascular adhesion, scleroedema, etc.
  • Ocular diseases associated with angiogenesis include corneal graft angiogenesis, neovascular glaucoma, diabetic retinopathy, corneal disease induced by angiogenesis, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasia, granular conjunctivitis, etc.
  • angiogenesis-related diseases may include chronic inflammatory diseases such as arthritis, cutaneous diseases such as psoriasis, capillarectasia, pyogenic granuloma, seborrheic dermatitis, acne, Alzheimer's disease and obesity.
  • Tumor growth and metastases are dependent upon angiogenesis (D'Amato RJ et al., Ophthalmology, 102(9), ppl261-1262, 1995 ; Arbiser JL, J. Am. Acad. Dermatol., 34(3), pp486-497, 1996 ; O'Brien KD et al. Circulation, 93(4), pp672-682, 1996 ; Hanahan D et al . , Cell, 86, pp353-364, 1996).
  • angiogenesis plays an important role in the growth and metastasis of cancers.
  • Tumor is supplied with nutrition and oxygen necessary for growth and proliferation through new blood vessels and the new blood vessels infiltrating into the tumors make the cancer cells being metastasized to enter the blood circulation system, thus supporting the metastasis of cancer cells (Folkman and Tyler, Cancer Invasion and metastasis, Biologic mechanisms and Therapy (S.B. Day ed.) Raven press, New York, pp94-103, 19771 Polverini PJ, Crit. Rev. Oral. Biol. Med., 6(3), pp230-247, 1995).
  • the major cause of death in cancer patients is metastasis and the reasons why the chemotherapies or immunotherapies being used clinically at present do not contribute to the increase in the survival rate of cancer patients are directed to metastasis.
  • Typical diseases resulting from angiogenesis includes macular degeneration, diabetic retinopathy, etc. that occur commonly in old age, premature infant's retinopathy, neovascular glaucoma, corneal disease induced by neovascularization, etc. (Adamis AP et al., Angiogenesis, 3, pp9-14, 1999). Among them, diabetic retinopathy that is one of the diabetic complications and a disease that retinal capillaries invade vitreous body to become blind.
  • Psoriasis characterized by red spots and scaly skin is a chronic proliferative disease occurring in skin and is accompanied with pain and malformation. Normally, keratinocytes proliferate once a month, however, in psoriasis patient, the keratinocytes proliferate at least once a week. For such rapid proliferation, a large quantity of blood is required, thus resulting in active angiogenesis (Folkman J, J. Invest. Dermatol., 59, pp40- 48, 1972).
  • angiogenesis inhibitors Since it is possible to apply angiogenesis inhibitors to agents for treating diseases associated with various angiogeneses, a variety of researches aimed at treating such diseases by inhibiting angiogenesis have continued to progress actively. Since such angiogenesis inhibitors should be administrated to patients for a long time, the most ideal inhibitor is one that should have low toxicity and be orally administrated. Accordingly, it is necessary to develop drugs that have low toxicity as angiogenesis inhibitors.
  • l-furan-2-yl-3-pyridin-2-yl-propenone has an excellent anti-angiogenesis activity and a cancer cell growth inhibitory effect and completed the present invention.
  • An object of the present invention is to provide a pharmaceutical composition comprising l-furan-2-yl-3-pyridin-2-yl-propenone for preventing and treating diseases, caused by angiogenesis, and cancer diseases.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising l-furan-2-yl-3- ⁇ yridin-2-yl-propenone expressed by chemistry figure 1 below as an active ingredient for preventing and treating diseases caused by angiogenesis, in combination with pharmaceutically acceptable carriers or excipients:
  • Such diseases caused by angiogenesis includes rheumatic arthritis, osteoarthritis, septic arthritis, psoriasis, corneal ulcer, senile macular degeneration, diabetic retinopathy, proliferative vitreous body retinopathy, premature retinopathy, ocular inflammation, conical cornea, Sjogren's syndrome, myopia eye tumor, cornea graft rejection, abnormal wound intention, bone disease, proteinuria, abdominal aortic aneurysm, regressive cartilage loss due to traumatic joint injury, demyelinating disease of central nervous system, hepatic cirrhosis, glomerular disease, premature rupture of embryonic membrane, inflammatory bowel disease, periodontitis, atherosclerosis, restenosis, inflammatory disease of central nervous system, Alzheimer's disease, skin aging or infiltration and metastasis of cancer.
  • Such cancer diseases include lung cancer, non-small cell lung cancer (NSCLC), colon cancer, bone cancer, pancreatic cancer, skin cancer, cephalic or cervical cancer, skin or eye melanoma, uterine cancer, ovarian cancer, rectal cancer, gastric cancer, anal cancer, colon cancer, breast cancer, fallopian tube carcinoma, endometrium carcinoma, cervical carcinoma, vaginal carcinoma, vulva carcinoma, Hodgkin' s disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocyte lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system (CNS) tumor, primary central nervous system lymphoma (PCNSL), spinal-cord tumor, brain stem glioma or pituitary adenoma.
  • CNS central nervous system
  • PCNSL primary
  • the compound of l-furan-2-yl-3-pyridin-2-yl- propenone in accordance with the present invention can be effectively used as a composition for preventing and treating diseases, caused by angiogenesis, and cancer diseases, since it inhibits the neovascularization and the growth of cancer cells in the chorioallantoic membrane models significantly, and also inhibits the growth of cancer and the metastasis of cancer cells in the athymic nude mice models.
  • Fig. 1 shows angiogenesis inhibitory effects of FPP-3 on glioblastoma cells
  • Figs. 2 to 7 show angiogenesis inhibitory effects of FPP-3 in HUVEC cells
  • Fig. 8 depicts volume changes of tumors according to FPP-3 treatments in athymic nude mice models
  • Fig. 9 illustrates cancer cell migration inhibitory effects of FPP-3 in HT-1080 cells
  • Figs. 10 to 13 illustrate cancer cell invasion inhibitory effects in HT-1080 cells of a control group and FPP-3 treated groups by concentrations
  • Figs. 14 and 15 illustrate MMP secretion inhibitory effects of FPP-3 in HT-1080 cells
  • Fig. 16 depicts VEGF secretion inhibitory effects of FPP-3 in HT-1080 cells!
  • Fig. 17 depicts a result of cancer cell toxicity test of FPP-3. [Best Mode]
  • a strong base such as potassium hydroxide, sodium hydroxide and the like, desirably, 34 mg of sodium hydroxide is dissolved in a low alcohol solvent of C 1 to C4 , desirably, ethanol at a temperature of 10 to 30°C under the presence of nitrogen
  • an aldehyde compound desirably, 54.85 mM of 2- ⁇ yridinecarboxaldehyde
  • the compound of l-furan-2-yl-3-pyridin-2-yl- propenone in accordance with the present invention obtained in such manner described above can be effectively used as a composition for inhibiting angiogeneses and for preventing and treating cancer diseases, since it inhibits the increase of neovascularization according to the treatment of neovascularization inducing materials such as vascular endothelial growth factor and fibroblast growth factor in the chicken chorioallantoic membrane (CAM) models, inhibits the neovascularization activated by grafting cancer cells into the chorioallantoic membrane, and further inhibits the volume expansion of glioblastoma in accordance with the above results.
  • neovascularization inducing materials such as vascular endothelial growth factor and fibroblast growth factor in the chicken chorioallantoic membrane (CAM) models
  • the compound of l-furan-2-yl-3- pyridin-2-yl-propenone in accordance with the present invention inhibits angiogenesis by human umbilical endothelial cells (HUVEC) dose-dependentIy, inhibits the volume expansion of tumors in the athymic nude mice models, into which HT-1080 human fibrosarcoma cells are grafted, inhibits metastasis of cancer cells by obstructing the migration and invasion of cancer cells in HT- 1080 human fibrosarcoma cells, and further inhibits the activation and expression of MMP and VEGF.
  • HUVEC human umbilical endothelial cells
  • the present invention provides an efficacious pharmaceutical composition
  • l-furan-2-yl-3-pyridin-2-yl-propenone prepared in the above process as an active ingredient for preventing and treating diseases, caused by angiogenesis, and cancer diseases, in combination with pharmaceutically acceptable carriers or excipients.
  • Doses and ways of application of the pharmaceutical composition comprising l-furan-2-yl-3-pyridin-2-yl-propenone expressed by chemistry figure 1 in accordance with the present invention may be varied based on the formulations and the use purposes thereof.
  • the pharmaceutical composition comprising the compound of the present invention for preventing and treating diseases, caused by angiogenesis, and cancer diseases is composed of 0.1 to 50% by weight of the compound based on the total weight of the composition.
  • composition comprising the compound of the present invention may further comprises suitable carriers, excipients or diluents used commonly in preparing pharmaceutical compositions.
  • the carriers, excipients or diluents that may be contained in the composition comprising the compound of the present invention are exemplified by lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • composition comprising the compound of the present invention may be prepared in various formulations, such as oral formulations including powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., agents for external application, suppository and sterilizing injection solutions.
  • oral formulations including powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., agents for external application, suppository and sterilizing injection solutions.
  • compositions comprising the compound of the present invention may be formulated into various dosage forms using diluents or excipients such as fillers, expanders, bonding agents, humectants, disintegrants, surfactants, etc.
  • Solid dosages for oral administration include tablets, pi 1 lets, powders, granules, capsules, etc.
  • Such solid dosages are prepared by mixing the compound of the present invention with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc.
  • lubricants such as magnesium stearate, talc, etc. may be added.
  • Liquid dosage forms for oral administration such as suspensions, internal solutions, emulsions, syrups, etc.
  • Dosage forms for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, suppositories, etc.
  • Non-aqueous solvents and suspensions may be prepared using propylene glycol, polyethylene glycol, vegetable oils such as olive oil, or injectable esters such as ethyl oleate.
  • bases for suppositories witepsol, macrogol, Tween 61, cacao oil, laurinic acid, and glycerogelatine are useful.
  • the dosages of the compound of the present invention may be varied according to various relevant factors, such as age, sex, weight. In general, 0.1 to 100 mg/kg of the compound of the invention can be administrated once or several times a day. Moreover, the dosages of the compound may be increased and decreased according to administration path, severity of disease, sex, weight, age, etc. Accordingly, the dosages do not limit the scope of the present invention in any aspect.
  • the pharmaceutical composition can be administrated to mammals such as mice, rats, livestock, humans, etc. through various paths.
  • mammals such as mice, rats, livestock, humans, etc.
  • it can be administrated by oral and parenteral (e.g., rectal, intravenous, intramuscular, cutaneous, intrauterine or intracerebroventricular injection) administrations.
  • parenteral e.g., rectal, intravenous, intramuscular, cutaneous, intrauterine or intracerebroventricular injection
  • 2-pyridinecarboxaldehyde (5.2 ml, 54.85 mM) was added to 34 mg of solid phase sodium hydroxide solution dissolved in ethanol at 25 ° C under the presence of nitrogen. The resulting solution was mixed with 2-acetylfuran (5 ml, 49.86 mmol) and stirred at 25°C for 3 hours. Subsequently, 80 ml of water was added to the mixture and the mixture was extracted with 120 ml of dichloromethane. The organic layer was washed with 80 m#x2 of water and 80 ml of saturated sodium chloride (NaCl) solvent and dried with sodium sulfate (Na2 SO4 ).
  • Fertilized eggs were purchased from Yeungnam University affiliated stock farm (Gyeongsan, Korea).
  • Chang liver cells that are a line derived from normal human liver, A172 human glioblastoma cells, SK-N-SH human neuroblastoma cells, HT-1376 human bladder cancer cells, HT-29 human colon cancer cells, HepG2 human hepatoma cells, HT-1080 human fibrosarcoma cells were purchased from ATCC (Rockville, MD, USA).
  • human umbilical vein endothelial cells (HUVEC) were purchased from Clonetics (San Diego, CA, USA)
  • Athymic nude mice aged 5 weeks were purchased from Orient Co., Ltd. (Seoul , Korea) .
  • 2-carboxaldehyde, 2-acetylfuran and cortisone acetate were purchased from Aldrich Chemical Co. (St. Louis, MO, USA), fibroblast growth factors (FGF) were from Invitrogen (USA), vascular endothelial growth factors (VEGF) were from R&D systems (Minneapolis, MN, USA), Tetrac and XT199 were supplied from the Pharmaceutical Research Institute of Albany and Albany College of Pharmacy (USA) and whatman filter discs were purchased from Whatman Inc. (UK).
  • TM spectrometry was used under the control of the Xcalibur software.
  • the silica gel Kieselgel 60 F254 (230 to 240 mesh) of Merck was applied thereto.
  • HT-29 human colon cancer cells HT-1376 human bladder cancer cells, HepG2 human hepatoma cells, SK-N-SH human neuroblastoma cells, A172 human glioblastoma cells, HT-1080 human fibrosarcoma cells and Chang liver cells were purchased from ATCC (Rockville, MD, USA).
  • Cells were cultured in a powdered Eagle' s minimum essential medium (MEM, Sigma Chemical Co.) containing 10% fetal bovine serum (GIBCO), 200 IU vd penicillin, 200 ⁇ g/id streptomycin, ImM sodium pyruvate in a humidifying incubator under the conditions of 37°C, 5% CO 2 and 95% air.
  • MEM powdered Eagle' s minimum essential medium
  • GEBCO fetal bovine serum
  • 200 IU vd penicillin 200 IU vd penicillin
  • 200 ⁇ g/id streptomycin ImM sodium pyruvate
  • the culture medium was replaced with a new
  • HUVEC cells were cultured in a flask coated with 0.2% gelatin. Then, the HUVEC cells were cultured in endothelial cell basal medium-2 (EBM-2, Clonetics, San Diego, CA) containing fetal bovine serum (FBS), hydrocortisone, human basic fibroblast growth factor (hFGF-B) , vascular endothelial growth factor (VEGF), human recombinant insulin-like growth factor (R3-IGF-1), ascorbic acid, human epidermal growth factor (hEGF) and heparin.
  • EBM-2 endothelial cell basal medium-2
  • FBS fetal bovine serum
  • hFGF-B human basic fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • R3-IGF-1 human recombinant insulin-like growth factor
  • ascorbic acid human epidermal growth factor (hEGF) and heparin.
  • HUVEC cells between the first and sixth passages were
  • chorioallantoic membrane assay was carried out (Nguyen M et al . , Microvascular Res., 47, pp31-40, 1994). Fertilized chicken eggs were cultured keeping the temperature at 37°C and the relative humidity at 55%. On the tenth day, the first small hole was made in the region of air sac and the second hole was dug in the flat region of egg, through which a window is to be made, using a hypodermic needle (Greencross Medical Science, Korea).
  • Each egg was deflated through the first hole in the region of the air sac so that the chorioallantoic membrane was split from the egg shell. Subsequently, a window was made by cutting the second hole using a grinding wheel (Multipro 395JA, Dremel, Mexico). Next, whatman filter discs #1 (Whatman Inc. USA) were treated with 3 mg/ml of cortisone acetate and dried. The filter discs were drenched with the fibroblast growth factor (FGF) in a concentration of 15 ng/CAM and the vascular endothelial growth factor (VEGF) in a concentration of 20 ng/CAM.
  • FGF fibroblast growth factor
  • VEGF vascular endothelial growth factor
  • the filter disc was put on the vessels through the window previous made and the compound FPP-3 of Example 1 in accordance with the present invention was dissolved in dimethylsulfoxide (DMSO) and diluted with phosphate buffered saline (PBS) to treat by concentrations (100 ng, 1 ⁇ g, 5 ⁇ g, 10 ⁇ g and 20 ⁇ g ).
  • DMSO dimethylsulfoxide
  • PBS phosphate buffered saline
  • concentrations 100 ng, 1 ⁇ g, 5 ⁇ g, 10 ⁇ g and 20 ⁇ g
  • the CAMs, on which each filter disc was placed were separated and washed with PBS to take images using a stereomicroscope (Stemi SV6 stereomicroscope, Carl Zeiss, Germany) and Image- Pro Plus software (Media Cybernetics; Silver Spring, MD, USA).
  • the branch points were counted and the result data were analyzed (See Table D. [Table 1]
  • VEGF vascular endothelial growth factor
  • FGF fibroblast growth factor
  • the window was made in the same manner as Experimental Example 1 and C6 glioblastoma cells of 1X10 cells/25 ml were inoculated into the chorioallantoic membrane (CAM) through the window according to the method of Gu JW et al . (Gu JW et al . , Cancer, 103(2), pp422-431, 2000). After two hours from the inoculations, 10 ⁇ g/CAM of XT199 and Tetrac were treated, respectively, to positive control groups, and the compound FPP-3 of Example 1 was treated to the portions, into which the cancer cells were inoculated, by concentrations (5 and 10 ⁇ g/CAM) .
  • CAM portions in which tumor tissues were formed, were removed and washed with PBS to take images using a stereomicroscope (Stemi SV6 stereomicroscope, Carl Zeiss, Germany) and Image-Pro Plus software (Media Cybernetics; Silver Spring, MD, USA). Ultimately, the branch points were counted and the result data were analyzed (See Fig. 1). Moreover, the tumor tissues were weighed and kept in 10% formalin or liquid nitrogen for the purposes of RNA isolation and morphological study. [Table 2]
  • HUVEC cells were cultured in a 96-well plate.
  • the respective wells of the 96-well plate were coated with 40 ⁇ l of Matrigel (BD Bioscience, Bedford, MA) and then the 96-well plate was used after kept at 37°C for 30 minutes.
  • Matrigel BD Bioscience, Bedford, MA
  • HUVEC cells were suspended in endothelial cell basal medium-2 (EBM-2,
  • Fig. 2 shows HUVEC cells, not treated with FPP-3, as a control group
  • Fig. 3 shows HUVEC cells treated with 100 mM of FPP-3
  • Fig. 4 shows those treated with 500 mM of FPP-3
  • Fig. 5 shows those with 1 ⁇ M of FPP-3
  • Fig. 6 shows those with 5 ⁇ M of FPP-3
  • Fig. 7 shows those with 10 ⁇ M of FPP-3.
  • Athymic nude mice aged 5 weeks were allowed to take the feed and water freely under the circumstances where the temperature was kept at 21+1°C and the light was regulated such that a light-dark cycle was repeated every 12 hours.
  • Such athymic nude mice were applied to the experiment after kept under such circumstances for at least two days.
  • the animal experiment, to be described hereinafter, was carried out pursuant to the ethical provisions of the Korean National Institute of Health (KNIH).
  • V 1/2(Z,*PF 2 ) wherein V denotes a volume of tumor; L denotes a large diameter; and W denotes a small diameter.
  • the horizontal axis denotes the days after drug treatment based on the first FPP-3 treatment and the vertical axis denotes the volume increases of tumor (nun 3 ) measured in the athymic nude mice models.
  • the horizontal axis denotes the passages of time such as 0, 6, 12, and 24 hours (Hr)
  • the upper photographs denotes the cell migrations in the control group taken after treating HT-1080 cells like the above
  • the lower photographs denotes the cell migrations in the group treated with 30 ⁇ M of FPP-3 under the same conditions as the control group, the respective photographs being magnified 100 times.
  • the numerous HT-1080 cells were cultured in the upper and lower parts of the line of 1 mm in width formed by wounding the HT-1080 cells cultured in the culture plate (0 Hr). Subsequently, with the passage of time of 6 hours, 12 hours and 24 hours, the line of 1 mm in width vanished and the HT-1080 cells migrated along with the line of 1 mm in width in the control group. However, the HT-1080 cells in the group treated with FPP-3 hardly migrated along with the line of 1 mm in width even after the lapse of 24 hours. Accordingly, it could be confirmed that the compound FPP-3 inhibited the cancer cell migration remarkably.
  • the bottom side of the polycarbonate filter was coated with 20 I of type 1 collagen in a concentration of 0.5 mg/m£ and the top side thereof was coated with 20 i of matrigel (BD Bioscience, Bedford, MA) in a concentration of 1.5 mg/iM.
  • the lower region of the polycarbonate filter was filled with a medium containing 10% fetal bovine serum (FBS) and the HT-1080 cells were inoculated into the upper region of the polycarbonate filter.
  • FBS fetal bovine serum
  • the HT-1080 cells inoculated like the above were cultured at 37°C for 18 hours. Subsequently, the cells infiltrating the bottom side of the polycarbonate were fixed with methanol and dyed with hematoxylin and eosin.
  • HT-1080 cells 6 secretion in cancer cells, 1X10 HT-1080 cells were injected into the respective wells of 6-well plate.
  • the HT-1080 cells injected were cultured in MEM medium containing 10% fetal bovine serum (FBS) for 12 hours so that the HT-1080 cells adhered to the plate.
  • FBS fetal bovine serum
  • the MEM medium containing FBS was removed and the plate were washed with a MEM medium containing no serum.
  • the HT-1080 cells were cultured again in MEM medium containing no serum for 24 hours. Then, the supernatants were collected from the 6-well o
  • the supernatants collected from the 6-well plate were electrophoresed in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel containing gelatin. After the electrophoresis, the SDS-PAGE gel was washed twice with buffer solutions (50 mM Tris-HCl, pH 7.5 and 100 mM NaCl, 2.5% Triton X-IOO) to remove the SDS.
  • buffer solutions 50 mM Tris-HCl, pH 7.5 and 100 mM NaCl, 2.5% Triton X-IOO
  • the SDS-PAGE gels were cultured at 37 ° C in buffer solutions (5OmM Tris-HCl, pH7.5, 15OmM NaCl, 1OmM CaCl 2 , 0.02% NaN 3 ) and then dyed with 0.25% Coomassie Brilliant Blue R-250 solution (Sigma Chemical Co., St. Louis, MO) and destained.
  • buffer solutions 5OmM Tris-HCl, pH7.5, 15OmM NaCl, 1OmM CaCl 2 , 0.02% NaN 3
  • Coomassie Brilliant Blue R-250 solution Sigma Chemical Co., St. Louis, MO
  • Fig. 14 the respective lanes shows the activities of MMP-2 and MMP- 9 based on FPP-3 concentrations ( ⁇ M) treated to the respective HT-1080 cells for 24 hours.
  • the MMP-2 and MMP-9 are gelatinases responsible for the degradation of gelatins contained in the SDS-PAGE. Accordingly, it is possible to observe bands in the area where the MMP-2 and MMP-9 exist. First, it can be observed from Fig. 14, where FPP-3 was treated in concentrations from 0 ⁇ M to 30 ⁇ M, that the bands become dimmer as much as the concentration of FPP-3 treated becomes higher. Accordingly, it can be learned that the enzyme activities of MMP-2 and MMP-9 secreted from the HT- 1080 cells become lower as much as the concentration of FPP-3 treated becomes higher.
  • the first lane depicts the results obtained by treating no TPA and FPP-3 to the HT-1080 cells!
  • the second lane denotes the results obtained by treating 12 ng/m£ of TPA and treating no FPP-3 thereto;
  • the third lane denotes the results obtained by treating 12 ng/in£ of TPA and 20 ⁇ M of FPP-3 thereto;
  • the fourth lane denotes the results obtained by treating 12 ng/mt of TPA and 30 ⁇ M of FPP-3 thereto, respectively.
  • the MMP-9 protein having a relatively great size exists in the top side of the SDS-PAGE gel, and PRO-MMP-2 protein, a precursor of MMP-2 protein, and ACTIVE-MMP-2 protein, exist in the bottom side thereof.
  • the MMP-2 and MMP-9 as gelatinases degrade the gelatins contained in the SDS-PAGE to form bands shown in Fig. 15.
  • TPA (12-0-tetradecanoylphorbol-13-acetate)
  • the expressions of such MMP-2 and MMP-9 are increased.
  • the first lane shows no bands in MMP-9 and ACTIVE-MMP-2, since the HT-1080 cells were not stimulated by TPA.
  • a band is shown in PRO-MMP-2, a precursor of MMP-2 protein in the first lane.
  • the second lane denoting the results obtained by treating only TPA, bright bands are observed in MMP-9 and MMP-2.
  • the compound FPP-3 decreases the secretion of MMP-2 and MMP-9 activated by TPA in the HT-1080 cells.
  • VEGF vascular endothelial growth factor
  • HT-1080 cells were cultured in a 24-well plate with media containing no serum under the presence of FPP-3 of different concentrations for 24 hours.
  • HT-1080 cells used in the control group were not treated with FPP-3.
  • the supernatant media in the respective wells were collected to measure the concentrations of VEGF discharged from the cells.
  • the concentrations of VEGF discharged were measured using Quantikine human VEGF ELISA kit (R&D system, Minneapolis, MN). The measurement of VEGF concentrations was carried out pursuant to the usage of the Quantikine human VEGF ELISA kit.
  • Fig. 16 depicts VEGF secretion inhibitory effects of FPP-3 in HT-1080 cells, in which the horizontal axis denotes the concentrations ( ⁇ M) of FPP-3 and the vertical axis denotes the concentrations (ng/roC) of VEGF.
  • the CONTROL represents the results obtained by treating no FPP-3 to HT-1080 cells.
  • VEGF was secreted most much in the control group and the concentration of VEGF secreted from the HT- 1080 cells was decreased as much as the concentration of FPP-3 was increased by 1, 10 and 20 ⁇ M. Accordingly, it can be confirmed that the compound FPP-3 decreases the secretion of VEGF secreted from the HT-1080 cancer cells.
  • DMSO dimethylsulfoxide
  • the compound FPP-3 shows toxicity for human cancer cells of various types only in a high concentration but does not show the toxicity in a low concentration.
  • the toxicity concentration for Chang cells shows more than 50 ⁇ M of 50% inhibitory concentration (IC50), thus representing the low cell toxicity.
  • the above ingredients were mixed with one another and tableted according to a conventional method of preparing tablets, thus preparing a tablet.
  • the above ingredients were mixed with one another and packed in a gelatin capsule according to a conventional method of preparing capsules, thus preparing a capsule.
  • An injection was prepared to 2m£ of an ampoule containing the above ingredients according to a conventional method of preparing injections.
  • the above ingredients were added to purified water to be dissolved and lemon fragrance of optimum dose was added thereto. Then the above ingredients were mixed with one another and purified water was added thereto to regulate the resulting solution as HXM in total.
  • the solution was filled into a brown bottle and sterilized according to a conventional method of preparing liquids, thus preparing a liquid.

Abstract

L'invention concerne une composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propénone, exprimée par la structure chimique 1 et présentant une activité anti-angiogénique et une activité inhibitrice du cancer. Le composé de l'invention peut effectivement être utilisé comme une composition destinée à prévenir et à traiter des maladies causées par l'angiogenèse et des maladies cancéreuses, puisqu'il inhibe considérablement la néovascularisation et la croissance de cellules cancéreuses dans les modèles de membranes chorio-allantoïdes, ainsi que l'évolution du cancer et la métastase de cellules cancéreuses dans les modèles de souris nude athymiques.
PCT/KR2006/001990 2005-09-13 2006-05-25 Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer WO2007032591A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2005-0085356 2005-09-13
KR20050085356 2005-09-13
KR1020060046746A KR100779610B1 (ko) 2005-09-13 2006-05-24 1-퓨란-2-일-3-피리딘-2-일-프로페논을 함유하는혈관신생으로 인한 질환 및 암질환의 예방 또는 치료용약학조성물
KR10-2006-0046746 2006-05-24

Publications (1)

Publication Number Publication Date
WO2007032591A1 true WO2007032591A1 (fr) 2007-03-22

Family

ID=37865149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/001990 WO2007032591A1 (fr) 2005-09-13 2006-05-25 Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer

Country Status (1)

Country Link
WO (1) WO2007032591A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106599A1 (fr) * 2010-02-25 2011-09-01 Alcon Research, Ltd. Procédé d'accélération de cicatrisation de plaie de la cornée
WO2014160940A2 (fr) * 2013-03-29 2014-10-02 Avoscience, Llc Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques
US10905673B2 (en) 2016-04-27 2021-02-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0476646A1 (fr) * 1990-09-20 1992-03-25 Merrell Pharmaceuticals Inc. Inhibiteurs de l'incorporation de calcium
WO1997033870A1 (fr) * 1996-03-15 1997-09-18 Ss Pharmaceutical Co., Ltd. Nouveaux derives de pyridine et medicaments contenant ces derives en qualite d'ingredient actif

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0476646A1 (fr) * 1990-09-20 1992-03-25 Merrell Pharmaceuticals Inc. Inhibiteurs de l'incorporation de calcium
WO1997033870A1 (fr) * 1996-03-15 1997-09-18 Ss Pharmaceutical Co., Ltd. Nouveaux derives de pyridine et medicaments contenant ces derives en qualite d'ingredient actif

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAHNG Y. ET AL.: "Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 2559 - 2562, XP004841239 *
LEE E.-S. ET AL.: "Inhibition of nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production by propenone compound through blockade of nuclear factor(NF)-kappaB activation in cultured murine macrophage", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 27, no. 5, 2004, pages 617 - 620, XP003010235 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106599A1 (fr) * 2010-02-25 2011-09-01 Alcon Research, Ltd. Procédé d'accélération de cicatrisation de plaie de la cornée
WO2014160940A2 (fr) * 2013-03-29 2014-10-02 Avoscience, Llc Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques
WO2014160940A3 (fr) * 2013-03-29 2014-12-31 Avoscience, Llc Composés de furane, pyrrole et thiophène lipidiques pour le traitement du cancer, de troubles neurologiques et de troubles fibrotiques
US9371302B2 (en) 2013-03-29 2016-06-21 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer
US9814694B2 (en) 2013-03-29 2017-11-14 Avioscience, LLC Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
US10085962B2 (en) 2013-03-29 2018-10-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
US10525031B2 (en) 2013-03-29 2020-01-07 Avoscience, Llc Lipid furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
US11058663B2 (en) 2013-03-29 2021-07-13 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
US11833129B2 (en) 2013-03-29 2023-12-05 Avoscience, Llc Thiophene compound for treatment of exfoliating glaucoma
US10905673B2 (en) 2016-04-27 2021-02-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis
US11602518B2 (en) 2016-04-27 2023-03-14 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis

Similar Documents

Publication Publication Date Title
KR100750657B1 (ko) 소목 추출물 및 이로부터 분리된 화합물의 용도
KR100903030B1 (ko) 멜리사엽 추출물 분획 및 이를 포함하는 조성물
JP6502919B2 (ja) アミドピリジンオール誘導体またはその薬剤学的に許容可能な塩、及びそれを有効成分として含有する薬学組成物
KR20020035855A (ko) 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
Cummins et al. Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-κB pathway
US7482027B2 (en) Composition for the prevention or treatment of diseases associated with angiogenesis
WO2007032591A1 (fr) Composition comprenant 1-furan-2-yl-3-pyridine-2-yl-propenone presentant une activite anti-angiogenique et une activite inhibitrice du cancer
KR101271593B1 (ko) 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항혈관신생효과를 갖는 조성물
US9505757B2 (en) Pharmaceutical composition comprising bicyclic pyridinol derivatives for preventing or treating diseases caused by angiogenesis
KR101481709B1 (ko) Ｓａｃ－１００４ 복합체를 유효성분으로 포함하는 발기부전 예방 또는 치료용 조성물
KR100825120B1 (ko) 잎새버섯 추출물을 함유하는 혈관신생으로 인한 질환 및암질환의 예방 또는 치료용 약학조성물
KR100779610B1 (ko) 1-퓨란-2-일-3-피리딘-2-일-프로페논을 함유하는혈관신생으로 인한 질환 및 암질환의 예방 또는 치료용약학조성물
KR100465229B1 (ko) 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
KR101048594B1 (ko) 혈관신생 및 암의 성장을 억제하는 카나비노이드 유도체를 함유하는 약학조성물
RU2291706C1 (ru) Применение флаволигнанов для подавления избыточной и патологической пролиферации эндотелия сосудов
KR20160129322A (ko) 갈란진 또는 캠퍼롤을 포함하는 항노화 조성물
KR101059321B1 (ko) 해면 추출 분획물을 유효성분으로 함유하는 ｍｍｐ―９또는 ｍｍｐ―２의 과다발현에 기인한 질환의 예방 및치료용 조성물
KR101727114B1 (ko) 도라지 사포닌 및 이로부터 분리된 플라티콘산 a를 유효성분으로 함유하는 혈관 신생 억제용 조성물
KR101048584B1 (ko) 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물
KR20150024607A (ko) 오수유 추출물 또는 이로부터 분리된 루타에카르핀 또는 리모시트린 3-루티노시드를 유효성분으로 함유하는 세포 노화 억제용 조성물
KR20160118405A (ko) 황련 수추출물을 유효성분으로 함유하는 신생혈관형성 억제 활성을 갖는 약학적 조성물
KR100930365B1 (ko) 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물
KR20180072632A (ko) 복분자 수추출물을 유효성분으로 함유하는 신생혈관형성 억제 활성을 갖는 약학적 조성물
KR20050030653A (ko) 혈관신생 억제활성을 갖는 2'-하이드록시-4'-메톡시칼콘및 이를 포함하는 항암제
KR20170101868A (ko) 복분자 수추출물을 유효성분으로 함유하는 신생혈관형성 억제 활성을 갖는 약학적 조성물

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06768632

Country of ref document: EP

Kind code of ref document: A1